Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Artesunate, Imatinib, and Infliximab in Covid-19: A Rapid Review and Meta-Analysis of Current Evidence Publisher Pubmed



Amani B1 ; Zareei S2 ; Amani B1 ; Zareei M3 ; Zareei N4 ; Shabestan R5 ; Akbarzadeh A5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Cell & Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran
  3. 3. Department of Health Services Management, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  5. 5. Department of Biostatistics and Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Source: Immunity# Inflammation and Disease Published:2022


Abstract

Background and Objective: Despite the pervasive vaccination program against coronavirus disease 2019 (COVID-19), fully vaccinated people are still being infected by severe acute respiratory syndrome coronavirus 2, making an effective and safe therapeutic intervention a crucial need for the patients' survival. The purpose of the present study is to seek available evidence for the efficacy and safety of three promising medications artesunate, imatinib, and infliximab against COVID-19. Methods: A literature search was conducted in PubMed, Cochrane Library, medRxive, and Google Scholar up to January 2022. Furthermore, the clinical trial databases were screened to find more citations. The Cochrane Collaboration tool and Newcastle–Ottawa scale were used to assess the included studies. Meta-analysis was performed using RevMan 5.4.1. Results: Five published studies were identified as eligible. Meta-analysis showed that there was no significant difference between the infliximab and control groups in terms of mortality rate (risk ratio [RR]: 0.65; 95% confidence interval [CI]: 0.40–1.07; p = 0.09). However, a significant difference was observed between the two groups for the hospital discharge (RR: 1.37; 95% CI: 1.04–1.80; p = 0.03). No remarkable clinical benefit was observed in favor of using imatinib for COVID-19 patients. Artesunate showed significant improvement in patients with COVID-19. Conclusion: In the present, limited evidence exists for the efficacy and safety of artesunate, imatinib, and infliximab in patients with COVID-19. The findings of WHO's Solidarity international trial will provide further information regarding these therapeutic interventions. © 2022 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
Related Docs
View other Related Docs
1. Safety and Efficacy of Imatinib, Nilotinib, and Artesunate in Covid-19 Patients: A Systematic Review of Current Evidence, Anti-Infective Agents (2024)
2. Lopinavir/Ritonavir for Covid-19: A Systematic Review and Meta-Analysis, Journal of Pharmacy and Pharmaceutical Sciences (2021)
3. The Possible Role of Novel Coronavirus 2019 Proteins in the Development of Drugs and Vaccines, Journal of Applied Biotechnology Reports (2020)
4. A Review of Covid-19: The Main Ways of Transmission and Some Prevention Solutions, Clinical Symptoms, More Vulnerable Human Groups, Risk Factors, Diagnosis, and Treatment, Journal of Environmental Treatment Techniques (2020)
5. The Development of New Treatment Options for Echinococcosis, Reviews and Research in Medical Microbiology (2015)
6. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors, Current Hematologic Malignancy Reports (2019)
7. Potential Therapeutic Options for Covid-19: An Update on Current Evidence, European Journal of Medical Research (2022)
8. Estimation of the Prevalence and Direct Medical Costs of Chronic Myeloid Leukemia in the I.R. of Iran in the Era of Tyrosine Kinase Inhibitors, Asia-Pacific Journal of Clinical Oncology (2017)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (1)
Marjan Yaghmaie (1)
Other Related Docs
9. Imatinib Efficacy, Safety and Resistance in Iranian Patients With Chronic Myeloid Leukemia: A Review of Literature, International Journal of Hematology-Oncology and Stem Cell Research (2021)
10. Cardiovascular Diseases Burden in Covid-19: Systematic Review and Meta-Analysis, American Journal of Emergency Medicine (2021)
11. Risk Factors for Mortality in Patients With Coronavirus Disease 2019 (Covid-19) Infection: A Systematic Review and Meta-Analysis of Observational Studies, Aging Male (2021)
12. Efficacy and Safety of Arbidol (Umifenovir) in Patients With Covid-19: A Systematic Review and Meta-Analysis, Immunity# Inflammation and Disease (2021)
13. Covid-19: Our Current Knowledge of Epidemiology, Pathology, Therapeutic Approaches, and Diagnostic Methods, Anti-Cancer Agents in Medicinal Chemistry (2021)
14. Epidemiological Characteristics of Covid-19 Patients in Mazandaran, Iran, 2021, Journal of Occupational Health and Epidemiology (2023)
15. Potential Limitations in Systematic Review Studies Assessing the Effect of the Main Intervention for Treatment/Therapy of Covid-19 Patients: An Overview, Frontiers in Medicine (2022)
16. Can Anti-Parasitic Drugs Help Control Covid-19?, Future Virology (2022)
17. Cardiac Injury Is Associated With Severe Outcome and Death in Patients With Coronavirus Disease 2019 (Covid-19) Infection: A Systematic Review and Meta-Analysis of Observational Studies, European Heart Journal: Acute Cardiovascular Care (2020)
18. Liver Injury Is Associated With Severe Coronavirus Disease 2019 (Covid-19) Infection: A Systematic Review and Meta-Analysis of Retrospective Studies, Hepatology Research (2020)